RxDoctor Payments Data

Charlene Maher

Psychiatric/Mental Health · Medford, NYNPI 1598898587

Payments from drug & device makers

$6,673in general payments, 2019–2025

Across 330 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$989
  • Neurocrine Biosciences, Inc.$862
  • Teva Pharmaceuticals USA, Inc.$822
  • Otsuka America Pharmaceutical, Inc.$670
  • Lundbeck LLC$624
  • AbbVie$576
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$6,48697%
  • Education$1863%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,673 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$42,343
Medicare patients
113
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole91$136,475
Invega SustennaPaliperidone Palmitate11$35,798
Lurasidone Hcl60$26,092
VraylarCariprazine Hcl16$22,536
TrintellixVortioxetine Hydrobromide16$7,901
Clozapine129$7,755
Desvenlafaxine Succinate ErDesvenlafaxine Succinate100$6,898
Atomoxetine Hcl64$6,197
Aripiprazole142$5,848
VyvanseLisdexamfetamine Dimesylate14$5,101
Quetiapine Fumarate ErQuetiapine Fumarate32$4,991
Clozapine OdtClozapine11$4,354
Bupropion XlBupropion Hcl237$3,870
Olanzapine200$3,283
Alprazolam260$3,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$670$136,47591 claims
Johnson & JohnsonInvega Sustenna$168$35,79811 claims
AbbVieVraylar$576$22,53616 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$92$13,00230 claims
Almatica Pharma LLCSertraline Hcl$146$1,326108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Medford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →